NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Current Liabilities

9 Months Ended

Jun. 30, 2021

8. Accrued Expenses and Other Current Liabilities

The Company’s accrued expenses and other current liabilities consisted of the following:


	As of June 30,		As of September 30,
	2021		2020
Accrued compensation and benefits	$	176,930	$	88,527
Accrued consulting settlement		100,000		—
Accrued professional fees		223,845		241,755
Accrued research and development		227,246		41,313
Accrued franchise tax		56,176		155,865
Accrued patent expenses		162,237		24,716
Other accrued expenses		91,707		3,707
Total	$	1,038,141	$	555,883